University of Pittsburgh Medical Center
Pittsburgh, Pennsylvania, 15213, United States
Location status: Recruiting
Location contact
Jill Morris-Tillman
CONTACT
Mary L Phillps, MD, MD
PRINCIPAL_INVESTIGATOR
NCT Number: NCT06081426
The investigators aim to examine the effect of the ketogenic diet on brain activity, metabolism, and emotions in adults with Bipolar Disorder (BD).
Interested in participating?
Request Info18 year–40 year
All sexes
Interventional
Not applicable
Pittsburgh, Pennsylvania, 15213, United States
Location status: Recruiting
Jill Morris-Tillman
CONTACT
Mary L Phillps, MD, MD
PRINCIPAL_INVESTIGATOR
The investigators hypothesize that a ketogenic diet will enhance levels of the ketone body β-Hydroxybutyrate (beta OHB), resulting in reduced mania/hypomania severity and predisposition to mania/hypomania in individuals with BD. To test this hypothesis in depth, the investigators will use a novel, multidisciplinary mechanistic study using multimodal neuroimaging, peripheral markers of mitochondrial metabolism, and participant-derived induced pluripotent stem cell (iPSC)-derived organoids.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
All participants:
BD hypomanic group (n=30):
BD euthymic group (n=30):
Healthy Control (HC) Group (n=30):
Exclusion criteria
All participants:
BD hypomanic group:
BD euthymic group:
Healthy Control (HC) Group
Consuming a non-ketogenic diet
Consuming a ketogenic diet
Participants without Bipolar Disorder will not participate in the diet phases of the study
Time frame: Baseline Scan 1 (all participants)
The blood oxygen level-dependent (BOLD) signal indicates brain activity and connectivity
Time frame: End of first dietary phase (8-10 weeks) (participants with Bipolar Disorder)
The blood oxygen level-dependent (BOLD) signal indicates brain activity and connectivity
Time frame: End of second dietary phase (8-10 weeks) (participants with Bipolar Disorder)
The blood oxygen level-dependent (BOLD) signal indicates brain activity and connectivity
Time frame: Baseline Scan 1 (all participants)
The Young Mania Rating Scale (YMRS) indicates the level of manic symptoms with a total score that varies between zero (better outcome) and 60 (worse outcome)
Time frame: Scan 2 at end of first dietary phase (8-10 weeks) (participants with Bipolar Disorder)
The Young Mania Rating Scale (YMRS) indicates the level of manic symptoms with a total score that varies between zero (better outcome) and 60 (worse outcome)
Time frame: Scan 3 at end of second dietary phase (8-10 weeks) (participants with Bipolar Disorder)
The Young Mania Rating Scale (YMRS) indicates the level of manic symptoms with a total score that varies between zero (better outcome) and 60 (worse outcome)
Time frame: Baseline (all participants)
Fasting glucose blood levels
Time frame: Baseline (all participants)
Fasting lipid blood levels
Time frame: Baseline (all participants)
Fasting levels of total protein in the blood
Time frame: Baseline (all participants)
Fasting levels of albumin in the blood
Time frame: Baseline (all participants)
Fasting levels of bilirubin in the blood
Time frame: Baseline (all participants)
Fasting levels of liver enzyme in the blood
Time frame: Halfway point through first dietary phase (4-5 weeks) (participants with Bipolar Disorder)
Fasting glucose blood levels
Time frame: Halfway point through first dietary phase (4-5 weeks) (participants with Bipolar Disorder)
Fasting lipid blood levels
Time frame: Halfway point through first dietary phase (4-5 weeks) (participants with Bipolar Disorder)
Fasting levels of total protein in the blood
Time frame: Halfway point through first dietary phase (4-5 weeks) (participants with Bipolar Disorder)
Fasting levels of albumin in the blood
Time frame: Halfway point through first dietary phase (4-5 weeks) (participants with Bipolar Disorder)
Fasting levels of bilirubin in the blood
Time frame: Halfway point through first dietary phase (4-5 weeks) (participants with Bipolar Disorder)
Fasting levels of liver enzyme in the blood
Time frame: End of first dietary phase (8-10 weeks) (participants with Bipolar Disorder)
Fasting glucose blood levels
Time frame: End of first dietary phase (8-10 weeks) (participants with Bipolar Disorder)
Fasting lipid blood levels
Time frame: End of first dietary phase (8-10 weeks) (participants with Bipolar Disorder)
Fasting levels of total protein in the blood
Time frame: End of first dietary phase (8-10 weeks) (participants with Bipolar Disorder)
Fasting levels of albumin in the blood
Time frame: End of first dietary phase (8-10 weeks) (participants with Bipolar Disorder)
Fasting levels of bilirubin in the blood
Time frame: End of first dietary phase (8-10 weeks) (participants with Bipolar Disorder)
Fasting levels of liver enzyme in the blood
Time frame: Halfway point through second dietary phase (4-5 weeks) (participants with Bipolar Disorder)
Fasting glucose blood levels
Time frame: Halfway point through second dietary phase (4-5 weeks) (participants with Bipolar Disorder)
Fasting lipid blood levels
Time frame: Halfway point through second dietary phase (4-5 weeks) (participants with Bipolar Disorder)
Fasting levels of total protein in the blood
Time frame: Halfway point through second dietary phase (4-5 weeks) (participants with Bipolar Disorder)
Fasting levels of albumin in the blood
Time frame: Halfway point through second dietary phase (4-5 weeks) (participants with Bipolar Disorder)
Fasting levels of bilirubin in the blood
Time frame: Halfway point through second dietary phase (4-5 weeks) (participants with Bipolar Disorder)
Fasting levels of liver enzyme in the blood
Time frame: End of second dietary phase (8-10 weeks) (participants with Bipolar Disorder)
Fasting glucose blood levels
Time frame: End of second dietary phase (8-10 weeks) (participants with Bipolar Disorder)
Fasting lipids blood levels
Time frame: End of second dietary phase (8-10 weeks) (participants with Bipolar Disorder)
Fasting levels of total protein in the blood
Time frame: End of second dietary phase (8-10 weeks) (participants with Bipolar Disorder)
Fasting levels of albumin in the blood
Time frame: End of second dietary phase (8-10 weeks) (participants with Bipolar Disorder)
Fasting levels of bilirubin in the blood
Time frame: End of second dietary phase (8-10 weeks) (participants with Bipolar Disorder)
Fasting levels of liver enzyme in the blood
Time frame: Baseline Scan 1 (all participants)
Gamma-aminobutyric acid (GABA) concentrations in the brain
Time frame: Baseline Scan 1 (all participants)
Glutamate concentrations in the brain
Time frame: Baseline Scan 1 (all participants)
Lactate concentrations in the brain
Time frame: Scan 2 at end of first dietary phase (8-10 weeks) (participants with Bipolar Disorder)
Gamma-aminobutyric acid (GABA) concentrations in the brain
Time frame: Scan 2 at end of first dietary phase (8-10 weeks) (participants with Bipolar Disorder)
Glutamate concentrations in the brain
Time frame: Scan 2 at end of first dietary phase (8-10 weeks) (participants with Bipolar Disorder)
Lactate concentrations in the brain
Time frame: Scan 3 at end of second dietary phase (8-10 weeks) (participants with Bipolar Disorder)
Gamma-aminobutyric acid (GABA) concentrations in the brain
Time frame: Scan 3 at end of second dietary phase (8-10 weeks) (participants with Bipolar Disorder)
Glutamate concentrations in the brain
Time frame: Scan 3 at end of second dietary phase (8-10 weeks) (participants with Bipolar Disorder)
Lactate concentrations in the brain
Time frame: Wrist actigraphy will be collected throughout the 8-10wk ketogenic diet and normal diet study intervals
Total sleep time will be assessed using wrist actigraphy. Wrist actigraphy will be collected continuously, at-home.
Time frame: Wrist actigraphy will be collected throughout the 8-10 wk ketogenic diet and normal diet study intervals.
Rest-activity rhythm interdaily stability will be assessed using wrist actigraphy. Wrist actigraphy will be collected continuously, at-home
Time frame: The first dietary phase (8-10 weeks) (participants with Bipolar Disorder)
Mood monitoring in real time in participants with Bipolar Disorder: rate mood on a scale of 1-7 with 1 being very low mood and 7 being very high mood
Time frame: The first dietary phase (8-10 weeks) (participants with Bipolar Disorder)
Energy monitoring in real time in participants with Bipolar Disorder: rate energy on a scale of 1-7 with 1 being very low energy and 7 being very high energy
Time frame: The first dietary phase (8-10 weeks) (participants with Bipolar Disorder)
Suicidality monitoring in real time in participants with Bipolar Disorder: answer yes or no to having self-harm/suicide thoughts and plans
Time frame: The second dietary phase (8-10 weeks) (participants with Bipolar Disorder)
Mood monitoring in real time in participants with Bipolar Disorder: rate mood on a scale of 1-7 with 1 being very low mood and 7 being very high mood
Time frame: The second dietary phase (8-10 weeks) (participants with Bipolar Disorder)
Energy monitoring in real time in participants with Bipolar Disorder: rate energy on a scale of 1-7 with 1 being very low energy and 7 being very high energy
Time frame: The second dietary phase (8-10 weeks) (participants with Bipolar Disorder)
Suicidality monitoring in real time in participants with Bipolar Disorder: answer yes or no to having self-harm/suicide thoughts and plans
Contact information is provided by the study sponsor or research team.
University of Pittsburgh
Other
Elucidating Neurobiological Mechanisms Underlying the Therapeutic Effect of the Ketogenic Diet in Bipolar Disorder (BD): a Multidisciplinary Mechanistic Study
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT00024635
Anxiety Disorders, Behavior
Bethesda, Maryland, United States
View Trial DetailsNCT07411222
Behavior, Bipolar Disorder
Bolu, Turkey (Türkiye)
View Trial DetailsNCT07534475
Bipolar Disorder, Bipolar and Related Disorders
Istanbul, Turkey (Türkiye)
View Trial DetailsNCT07286175
Bipolar Disorder, Bipolar and Related Disorders
Orange, California, United States
View Trial Details